CRONOS GROUP INC. (CRON) Spending and interest coverage
- R&D / revenue · 12 months: Value 2.99%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 3.60%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 2.99% | Research and development expense / revenue. Period ending 2026-06-30. $5.36M ÷ $179.09M × 100 ≈ 2.99% |
| Stock-based compensation / revenue · 12 months | 3.60% | Share-based compensation / revenue. Period ending 2026-06-30. $6.45M ÷ $179.09M × 100 ≈ 3.60% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 5.36M USD | Research and Development Expense |
| Revenue | 179.09M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 6.45M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -2.43M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.36M | $179.09M | $6.45M | $-2.43M | (m) | 2.99% | 3.60% | (m) | (m) |
| 2026-03-31 | $5.07M | $159.53M | $6.28M | $-15.16M | (m) | 3.18% | 3.93% | (m) | (m) |
| 2025-12-31 | $4.45M | $146.59M | $7.05M | $-17.39M | (m) | 3.04% | 4.81% | (m) | (m) |
| 2025-09-30 | $4.09M | $132.36M | $7.99M | $-21.26M | (m) | 3.09% | 6.04% | (m) | (m) |
| 2025-06-30 | $3.99M | $130.28M | $7.92M | $-54.42M | (m) | 3.06% | 6.08% | (m) | (m) |
| 2025-03-31 | $4.03M | $124.59M | $8.77M | $-64.65M | (m) | 3.23% | 7.04% | (m) | (m) |
| 2024-12-31 | $4.23M | $117.61M | $8.70M | $-76.53M | (m) | 3.60% | 7.40% | (m) | (m) |
| 2024-09-30 | $4.65M | $111.23M | $8.44M | $-86.80M | (m) | 4.18% | 7.59% | (m) | (m) |
| 2024-06-30 | $4.66M | $101.78M | $8.13M | $-74.92M | (m) | 4.57% | 7.99% | (m) | (m) |
| 2024-03-31 | $4.80M | $93.03M | $8.23M | $-79.98M | (m) | 5.16% | 8.85% | (m) | (m) |
| 2023-12-31 | $5.84M | $87.24M | $8.77M | $-84.80M | (m) | 6.70% | 10.05% | (m) | (m) |
| 2023-09-30 | $7.12M | $90.51M | $11.39M | $-103.61M | (m) | 7.86% | 12.58% | (m) | (m) |
| 2023-06-30 | $8.41M | $86.11M | $13.70M | $-109.17M | (m) | 9.77% | 15.91% | (m) | (m) |
| 2023-03-31 | $11.38M | $87.02M | $13.98M | $-110.78M | (m) | 13.08% | 16.07% | (m) | (m) |
| 2022-12-31 | $13.38M | $91.90M | $15.12M | $-124.84M | $13.00K | 14.56% | 16.45% | -9602.92× | Reported |
| 2022-09-30 | $17.47M | $94.81M | $12.99M | $-257.75M | (m) | 18.42% | 13.70% | (m) | (m) |
| 2022-06-30 | $21.37M | $94.30M | $11.39M | $-283.16M | (m) | 22.66% | 12.08% | (m) | (m) |
| 2022-03-31 | $22.27M | $86.86M | $11.34M | $-551.44M | (m) | 25.64% | 13.05% | (m) | (m) |
| 2021-12-31 | $23.33M | $74.44M | $10.15M | $-560.59M | $27.00K | 31.34% | 13.64% | -20762.74× | Reported |
| 2021-09-30 | $24.18M | $65.69M | $10.19M | $-416.37M | $-10.00K | 36.82% | 15.52% | (m) | Reported |
| 2021-06-30 | $22.45M | $56.64M | $15.44M | $-203.25M | $109.00K | 39.63% | 27.27% | -1864.72× | Reported |
| 2021-03-31 | $20.88M | $50.90M | $15.42M | $-177.75M | $185.00K | 41.02% | 30.30% | -960.79× | Reported |
| 2020-12-31 | $20.37M | $46.72M | $15.36M | $-179.35M | $186.00K | 43.59% | 32.88% | -964.23× | Reported |
| 2020-09-30 | $19.03M | $36.98M | $16.57M | $-184.88M | (m) | 51.47% | 44.80% | (m) | (m) |
| 2020-06-30 | $16.91M | $31.41M | $12.18M | $-174.42M | (m) | 53.82% | 38.79% | (m) | (m) |
| 2020-03-31 | $15.57M | $29.18M | $12.28M | $-156.42M | (m) | 53.38% | 42.10% | (m) | (m) |
| 2019-12-31 | $12.15M | $23.75M | $11.62M | $-121.48M | $1.24M | 51.18% | 48.92% | -97.66× | Reported |
| 2019-09-30 | (m) | $20.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $17.82M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $12.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $1.81M | $12.12M | $8.15M | $-21.34M | $139.00K | 14.97% | 67.25% | -153.53× | Reported |
| 2017-12-31 | $0.00 | $3.15M | $1.93M | $-6.12M | $101.00K | 0.00% | 61.36% | -60.60× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |